Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 280

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 12
Chunk 280
---
, or will be, a participant in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average
of our total assets at December 31, 2023 and 2022, as applicable) and in which any related person, had, or will have, a direct or indirect
material interest.

Participation
in 2024 Financings

August
2024 Financing

On
August 8, 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors 1,643,837 shares
of our common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,643,837
shares of our common stock. The warrants are immediately exercisable at an exercise price of $1.70 per share and expire five years from
the date of issuance. The combined purchase price for one share of common stock and one warrant was $1.825, resulting in gross proceeds
of approximately $3.0 million, before deducting placement agent and other offering expenses in the amount of approximately $0.5 million.
One of the purchasers was Jeffrey Meckler, our Chief Executive Officer and director, who purchased 84,932 shares of common stock and
warrants to purchase 84,932 shares of common stock (at the same price and upon the same terms as the other purchasers.

November
2024 Financing

On
November 25, 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors 1,817,017 shares
of our common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,817,017
shares of our common stock. The warrants are immediately exercisable at an exercise price of $1.05 per share and expire five years from
the date of issuance. The combined purchase price for one share of common stock and one warrant was $1.175, resulting in gross proceeds
of approximately $2.13 million, before deducting placement agent and other offering expenses in the amount of approximately $0.345 million.
One of the purchasers was Jeffrey Meckler, our Chief Executive Officer and director, who purchased 42,553 shares of common stock and
warrants to purchase 42,553 shares of common stock (at the same price and upon the same terms as the